1 / 12

FDA’s Evolution: Navigating Drug Changes in 2006

This comprehensive guide reflects on notable changes in the pharmaceutical landscape during 2006, including FDA updates, recalls data, and trends impacting regulatory practices. Learn about the revisions in drug labeling protocols, significant recalls, and the implications for firms. Stay informed about the Atlanta District’s high-risk firms, and understand the crucial organizational changes shaping drug regulation. Prepare for the future by examining past challenges and advancements in drug management to enhance compliance and safety.

verlee
Télécharger la présentation

FDA’s Evolution: Navigating Drug Changes in 2006

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. A Look Back at 2006 The year of the hurricane Organizational Change National and District Changes in programs Adverse Drug Experience A Look at Today FDA celebrates 100 years Program changes Increase in Atlanta District high risk firms Resource Changes A Look ahead Budget Submission for 07 Resource necessitated changes ASQ KeynoteFebruary 13, 2006

  2. New Content & Format of Labeling for Human Rx Drugs and Biological Products • First revision in 25 years • Applicable for new and recently approved products • Specific graphical requirements and reorganization of critical information to enable physicians to find the information quickly

  3. New Content & Format of Labeling for Human Rx Drugs and Biological Products • Highlights: provides immediate access to the most important prescribing information about benefits and risks • Table of Contents: easy reference to detailed safety and efficacy information • Date of initial product approval making it easy to determine how long the product has been on the market • Toll-free number and Internet reportinginformation for suspected adverse events to encourage more widespread reporting of suspected side effects

  4. Top 10 Atlanta Turbo CitesDrugs, Devices, Biologics, BIMO

  5. Top 10 Atlanta Turbo CitesDrugs

  6. Top 10 Atlanta Turbo CitesTies for Number 10

  7. DRUG RECALLS – FY 05 • CLASS I - 17 • CLASS II - 316 • CLASS III - 169

  8. DRUG RECALL – FY 05 • Class 1 (11 Rx / 6 OTC) • Class II (267 Rx / 49 OTC) • Class III (123 Rx / 46 OTC)

  9. REASONS FOR RECALL • CGMP DEVIATIONS (144) • FAILED DISSOLUTION TEST REQUIREMENTS (57) • MICROBIAL CONTAMINATION OF NON-STERILE PRODUCTS (31) • LACK OF EFFICACY (25) • IMPURITIES/DEGRADATION PRODUCTS (19)

  10. REASONS FOR RECALL • LACK OF STERILITY ASSURANCE (18) • PRODUCT STABILITY (16) • LABELING ERROR/DECLARED STRENGTH (13) • MISBRANDED/PROMOTIONAL LITERATURE CLAIMS (13)

  11. TIE FOR TENTH • LABELING ISSUES (MISCARTONED OR MISPACKED (12) • SUBPOTENT – SINGLE INGREDIENT DRUG (12) • SUPERPOTENT –SINGLE INGREDIENT DRUG (12)

  12. HELP NEEDED • Check if sending to right District • Identify NDA/NDA/BLA number of application, firm name and name of drug on cover of file. Beware of paper clips • Name of District firm identified. • Fasteners/overfill • Contact for listing of active applications

More Related